« Return to News | Drug Sponsors

AstraZeneca’s CEO Brennan to retire

Friday, April 27, 2012 11:30 AM

Global biopharmaceutical company AstraZeneca has announced that CEO and board member David Brennan has decided to retire, effective June 1, 2012.

Following Brennan's decision, the board has asked executive director and CFO Simon Lowth to act as interim CEO from June 1, 2012, until a permanent successor is in place. Julie Brown, vice president of group finance, will become interim CFO on the same date.

"After more than six years as chief executive officer of this great company I have decided that now is the right time to step down and allow a new leader to take the reins,” said Brennan. “The board's decision to appoint Simon Lowth as interim chief executive officer has my full support and I am confident that AstraZeneca will continue to have a positive impact on the lives of patients around the world and by doing so will deliver real value to our shareholders."

Brennan was appointed to his current role in January 2006 and is one of the longest serving chief executives in the pharmaceutical sector.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.